TrialsgrambetaRCTs are beautiful

DAPA-CKD

2020

Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease

In 4,304 patients with CKD with or without diabetes, dapagliflozin reduced the composite of ≥50% eGFR decline, ESKD or renal/CV death compared with placebo.

Result

Efficacy: ≥50% eGFR decline, ESKD, or renal or CV deathHR 0.61 (95% CI 0.51-0.72) · P < 0.001

Below 1 favours dapagliflozin, above 1 favours placebo.

Event rates
Absolute difference
5.3 points
NNT
19

Absolute difference and NNT are derived from the event rates.

Also reported: All-cause mortality HR 0.69.

Original publication
Subtopic
SGLT2 inhibitors
Design
Double-blind RCT, stopped early
Relevance
Practice-defining: a trial the guidelines cite as evidence.
Source
Heerspink HJL, et al. N Engl J Med. 2020;383(15):1436-1446.doi 10.1056/NEJMoa2024816

Discussion & critique

Extended SGLT2-inhibitor benefit to non-diabetic CKD; dialysis patients were excluded.

Discussed in podcasts